In the U.S., famous promotional posters for the weight loss drug Ozembik are being changed. What's the reason?

The U.S. Food and Drug Administration (FDA) has updated the information label for the diabetes drug Ozempic to reflect reported cases of intestinal obstruction in some patients.

The drug Ozempic and its counterpart Wegovy, both intended for weight loss, have gained popularity recently. Both drugs contain a substance called semaglutide, which is part of a family of drugs known as "GLP-1 analogs" that work by mimicking a hormone that the body naturally produces to slow the passage of food through the stomach, which helps the feeling of satiety for a longer period of time.

In a statement to CNN, the maker of the drug Ozempic and the Vegovy analog, Novo Nordisk, said patient safety is a top priority and that it works closely with the FDA to continuously monitor the safety of its drugs. The company stated: "Novo Nordisk supports the safety and efficacy of the drug Ozempic, and all of our medicines, when used in accordance with the directions for use and approved regulations. "

The labels for the medications Vegovi and Munjaro indicate that there are reports of a condition called intestinal obstruction in some patients using the drugs. The drug label "Ozempic" has been updated with the same mention. The label states, "Because these reactions were voluntarily reported by an unknown number of patients, their frequency cannot be reliably estimated or a causal relationship to drug intake can be established.

Some people taking the drugs Ozempic and Vegovy have also reported developing a condition called stomach paralysis. Experts believe that these cases are rare and may not be a direct result of taking the drugs themselves. In response to these allegations, Novo Nordisk told CNN last July that "GLP-1 analogs" have been widely studied and used for years. The company said in a statement, "Digestive symptoms are known side effects of the GLP-1 class of drugs." She also pointed out that "for semagluttide, most digestive side effects are mild or moderate and short-term. GLP-1 is known to cause delayed gastric emptying as indicated by the information label of each of our GLP-1 RA preparations. Symptoms of delayed gastric emptying, nausea and vomiting are listed as side effects. "

A Louisiana woman has filed a lawsuit against Novo Nordisk and Eli Lilly, alleging "serious digestive disorders" that she claims resulted from the use of Ozempic and Munjaro.